Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Sickle Cell Disease
About this trial
This is an interventional treatment trial for Sickle Cell Disease focused on measuring Plerixafor, 13-229
Eligibility Criteria
Inclusion Criteria:
- Patients must have confirmed and measurable Sickle Cell Disease, defined by SS or Sβ thalassemia confirmed by hemoglobin fractionation.
- ≥ 18 to 65 years of age
- Patient must have a ECOG performance status ≤2 or Karnofsky score > 70%
Patients must have acceptable organ and marrow function as defined below:
- WBC ≥ 3,000/μL
- ANC ≥ 1,500/μL
- platelets ≥150,000//μL
- Hemoglobin ≥ 6 gm/dL
- Calculated creatinine clearance ≥ 60ml/min * *Using the Cockcroft-gault equation [140 - Age(yrs)] [Weight(kg)] x 0.85 if Female 72 [Serum Creatinine (mg/dL]
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Each patient must be willing to participate as a research subject and must sign an informed consent form.
Exclusion Criteria:
Patients who are:
- Receiving or received treatment with an investigational agent within 4 weeks prior to entering the study OR
- have not recovered from adverse events due to agents administered more than 4 weeks earlier as determined by the treating physician.
- Patients with ALT(SGPT) > 2.5 X upper limit of normal
- Patients with a creatinine clearance of < 60 ml/min
Patients who have uncontrolled illness including, but not limited to:
- Ongoing or active infection
- Emergency room admission or hospitalization in the past 14 days
- Major surgery in the past 30 days
- Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician.
- Female patients who are pregnant or breast-feeding
- Patients with active hepatitis B, hepatitis C, or HIV infection
- Patients with poor cardiac function as defined by an ejection fraction < 40% are excluded due to potential poor tolerance of the fluid shifts with leukapheresis (only for patients enrolled on second phase of protocol for Leukapheresis).
Sites / Locations
- Memorial Sloan Kettering Cancer CenterRecruiting
- Weill Cornell Medical College
Arms of the Study
Arm 1
Experimental
Plerixafor
Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.